CEO Christopher Hall was paid $3,505,978 in fiscal year 2025, ↑ up 128.3% from fiscal year 2024, the 19th percentile of its disclosed peer group (SEC filing 0001193125-26-140038 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$3,505,978 ↑ Christopher Hall total, FY2025 | 19th CEO pay percentile vs peers | — CEO-to-median pay ratio | 99.49% Say-on-pay support, latest vote |
You have just read Personalis's Summary Compensation Table. The whole free brief as a PDF, sent in 2 minutes, with every figure cited — then a few short notes on the deeper PSNL reports.
We send the PDF within 2 minutes, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
PSNL's next annual pay disclosure, estimated April 2, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Christopher Hall | $618,000 | $0 | $853,050 | $1,784,728 | $247,200 | $0 | $3,000 | $3,505,978 |
| Chief Executive Officer and Director | ||||||||
| Aaron Tachibana | 545,900 | 0 | 272,250 | 656,150 | 131,000 | 0 | 3,000 | 1,608,300 |
| Chief Financial Officer and Chief Operating Officer | ||||||||
| Richard Chen | 530,450 | 0 | 272,250 | 656,150 | 127,300 | 0 | 3,000 | 1,589,150 |
| President, Executive Vice President, Research and Development and Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Christopher Hall | $3,505,978 | $1,535,960 | — | ↑ +1,970,018 |
| Aaron Tachibana | 1,608,300 | 1,011,594 | — | ↑ +596,706 |
| Richard Chen | 1,589,150 | 989,394 | — | ↑ +599,756 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
How we handle your data → Privacy
Each company listed discloses PSNL in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named PSNL in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| A. Blaine Bowman | Independent Director | $242,225 |
| Karin Eastham | Independent Director | $297,225 |
| Lonnie Shoff | Independent Director | $224,725 |
| Olivia K. Bloom | Independent Director | $244,725 |
| Woodrow Myers Jr., M.D | Independent Director | $229,725 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Christopher Hall | PSU | 117,500 | — | $935,300 |
| Christopher Hall | RSU | 56,250 | — | 447,750 |
| Aaron Tachibana | PSU | 37,500 | — | 298,500 |
| Richard Chen | PSU | 37,500 | — | 298,500 |
| Christopher Hall | Option | 57,292 | 2.67 | — |
| Christopher Hall | Option | 33,334 | 2.76 | — |
| Christopher Hall | Option | 166,667 | 1.61 | — |
| Christopher Hall | Option | 510,000 | 3.63 | — |
| Aaron Tachibana | Option | 37,500 | 2.76 | — |
| Aaron Tachibana | Option | 72,917 | 1.61 | — |
| Richard Chen | Option | 20,834 | 2.76 | — |
| Aaron Tachibana | Option | 187,500 | 3.63 | — |
| Richard Chen | Option | 72,917 | 1.61 | — |
| Richard Chen | Option | 187,500 | 3.63 | — |
We have a pay for performance compensation philosophy and culture. We believe that compensation should be designed to incentivize management to drive company performance to increase stockholder value.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-12 | 75,549,455 | 384,918 | 78,724 | 99.49% | Passed |
| 2025 | 2025-05-16 | 56,604,799 | 2,244,133 | 38,126 | 96.19% | Passed |
| 2024 | 2024-05-17 | 25,393,708 | 634,656 | 225,652 | 97.56% | Passed |
| 2023 | 2023-05-17 | 28,615,039 | 475,452 | 197,717 | 98.37% | Passed |
| 2022 | 2022-05-17 | 22,642,573 | 2,376,303 | 39,867 | 90.36% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-12 | 99.49%a |
| 2025 | 2025-05-16 | 96.19%b |
| 2024 | 2024-05-17 | 97.56%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Karin EasthamIndependent · Nominating and Corporate Governance (Chair) | $120,000 | $0 | $177,225 | — | $0 | $297,225 |
| Olivia K. BloomIndependent · Audit (Chair) | 67,500 | 0 | 177,225 | — | 0 | 244,725 |
| A. Blaine BowmanIndependent · Compensation (Chair) | 65,000 | 0 | 177,225 | — | 0 | 242,225 |
| Woodrow Myers Jr., M.DIndependent · Compensation · Nominating and Corporate Governance | 52,500 | 0 | 177,225 | — | 0 | 229,725 |
| Lonnie ShoffIndependent · Compensation | 47,500 | 0 | 177,225 | — | 0 | 224,725 |
| Christopher HallEmployee director · Nominating and Corporate Governance | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $352,500 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $352,500 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Personalis names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Personalis.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Twist Bioscience 1 | 2025 | Emily Leproust | $720,000 | $11,998,134 | $0 | $932,918 | $13,781,570 |
| 2 | GeneDx | 2025 | Katherine Stueland | 715,869 | 11,738,600 | 0 | 1,075,500 | 13,547,219 |
| 3 | Adaptive Biotechnologies 1 | 2025 | Chad Robins | 698,258 | 7,675,100 | 0 | 703,380 | 9,081,690 |
| 4 | Standard BioTools | 2025 | Michael Egholm | 680,256 | 5,337,883 | 1,671,363 | 1,120,000 | 8,823,502 |
| 5 | Veracyte | 2025 | Marc Stapley | 700,000 | 5,890,877 | 0 | 826,000 | 7,421,877 |
| 6 | CareDx | 2025 | John Hanna | 693,269 | 5,622,638 | 0 | 852,515 | 7,179,699 |
| 7 | Castle Biosciences | 2025 | Derek Maetzold | 751,350 | 4,977,208 | 0 | 1,036,863 | 6,786,771 |
| 8 | Mesa Laboratories 1 | 2026 | Gary Owens | 808,846 | 4,700,017 | 0 | 1,120,000 | 6,643,208 |
| 9 | Fulgent Genetics 1 | 2025 | Ming Hsieh | 1,000,000 | 4,000,000 | 0 | 1,207,000 | 6,207,000 |
| 10 | Quanterix | 2025 | Masoud Toloue | 670,950 | 1,170,000 | 2,729,998 | 674,172 | 5,250,745 |
| 11 | CytomX Therapeutics | 2025 | Sean McCarthy | 675,290 | 1,150,463 | 2,158,170 | 749,572 | 4,738,495 |
| 12 | Pacific Biosciences of California | 2025 | Christian Henry | 748,250 | 1,151,013 | 1,696,278 | 714,305 | 4,309,846 |
| 13 | OraSure Technologies | 2025 | Carrie Eglinton Manner | 721,000 | 3,394,188 | 0 | 173,040 | 4,292,228 |
| 14 | Personalis | 2025 | Christopher Hall | 618,000 | 853,050 | 1,784,728 | 247,200 | 3,505,978 |
| 15 | Codexis | 2025 | Alison Moore | 524,732 | 255,994 | 1,065,223 | 463,125 | 2,323,279 |
| 16 | Alector | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| 17 | Sutro Biopharma 1 | 2025 | William Newell | 239,693 | 0 | 0 | 0 | 1,671,311 |
| — | Akoya Biosciences | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Personalis | not disclosed | not disclosed | not disclosed | Aon |
| Adaptive Biotechnologies 1 | not disclosed | RSU 50 · PSU 50 | not disclosed | Semler Brossy Consulting Group, LLC |
| Akoya Biosciences | not disclosed | not disclosed | not disclosed | not disclosed |
| Alector | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| CareDx | not disclosed | RSU 70 · PSU 30 | No | Alpine Rewards |
| Castle Biosciences | 138% | RSU 50 · PSU 50 | No | AON (AON's Human Capital Solutions Practice, a division of AON plc) |
| Codexis | 95% | not disclosed | not disclosed | Pearl Meyer |
| CytomX Therapeutics | not disclosed | not disclosed | not disclosed | Aon |
| Fulgent Genetics 1 | 120.7% | PSU 60 · RSU 40 | No | USI |
| GeneDx | 150% | PSU 50 · RSU 50 | No | Pearl Meyer |
| Mesa Laboratories 1 | 125% | PSU 50 · RSU 50 | No | Frederic W. Cook & Co, Inc. |
| OraSure Technologies | 24.0% | RSU 50 · PSU 50 | Yes — Relative TSR performance vs peer group | Pay Governance |
| Pacific Biosciences of California | 95% | not disclosed | not disclosed | Aon Human Capital Solutions |
| Quanterix | 95% | Options 70 · RSU 30 | not disclosed | PayGov |
| Standard BioTools | 160% | not disclosed | not disclosed | Pearl Meyer |
| Sutro Biopharma 1 | 115% | Options 59 · RSU 41 | not disclosed | FW Cook |
| Twist Bioscience 1 | 129.6% | PSU 50 · RSU 50 | No | not disclosed |
| Veracyte | 118% | PSU 50 · RSU 50 | No | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Christopher Hall | DEF 14A | 2026-04-02 | 0001193125-26-140038 | Section “Executive Compensation”. As printed: 3,505,978. Filing ↗machine: r2 · c25 · span 489936–489945 |
| 2 | Section 01, Aaron Tachibana | DEF 14A | 2026-04-02 | 0001193125-26-140038 | Section “Executive Compensation”. As printed: 1,608,300. Filing ↗machine: r4 · c25 · span 509811–509820 |
| 3 | Section 01, Richard Chen | DEF 14A | 2026-04-02 | 0001193125-26-140038 | Section “Executive Compensation”. As printed: 1,589,150. Filing ↗machine: r6 · c25 · span 529710–529719 |
| 4 | Section 08, Karin Eastham | DEF 14A | 2026-04-02 | 0001193125-26-140038 | Section “Director Compensation”. As printed: 297,225. Filing ↗machine: span 1396025–1396251 |
| 5 | Section 08, Olivia K. Bloom | DEF 14A | 2026-04-02 | 0001193125-26-140038 | Section “Director Compensation”. As printed: 244,725. Filing ↗machine: span 1383487–1383713 |
| 6 | Section 08, A. Blaine Bowman | DEF 14A | 2026-04-02 | 0001193125-26-140038 | Section “Director Compensation”. As printed: 242,225. Filing ↗machine: span 1389757–1389983 |
| 7 | Section 08, Woodrow Myers Jr., M.D | DEF 14A | 2026-04-02 | 0001193125-26-140038 | Section “Director Compensation”. As printed: 229,725. Filing ↗machine: span 1402303–1402529 |
| 8 | Section 08, Lonnie Shoff | DEF 14A | 2026-04-02 | 0001193125-26-140038 | Section “Director Compensation”. As printed: 224,725. Filing ↗machine: span 1408569–1408795 |
| 9 | Section 08, Christopher Hall | DEF 14A | 2026-04-02 | 0001193125-26-140038 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 10 | Section 06, 2026 vote | Form 8-K | 2026-05-13 | 0001193125-26-221846 | Item 5.07 · say-on-pay result. As reported: 99.49% (votes for as printed: 75,549,455). Filing ↗ |
| 11 | Section 06, 2025 vote | Form 8-K | 2025-05-19 | 0000950170-25-074346 | Item 5.07 · say-on-pay result. As reported: 96.19% (votes for as printed: 56,604,799). Filing ↗ |
| 12 | Section 06, 2024 vote | Form 8-K | 2024-05-21 | 0000950170-24-062886 | Item 5.07 · say-on-pay result. As reported: 97.56% (votes for as printed: 25,393,708). Filing ↗ |
| 13 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 14 | Section 09b board cost (computed) | Computed | — | — | Cash 352,500 + equity 0 + all other 0 = 352,500, summed across the director compensation table rows.machine: formula: Σ = 352,500 |
| 15 | Twist Bioscience 1, Section 10b CEO total | DEF 14A | 2026-01-06 | 0001581280-26-000006 | CEO total compensation as printed in Twist Bioscience 1's own proxy. As printed: 13,781,570. Filing ↗machine: t34 · r2 · c15 · span 1510951–1510961 |
| 16 | GeneDx, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001818331-26-000030 | CEO total compensation as printed in GeneDx's own proxy. As printed: 13,547,219. Filing ↗machine: span 565318–565328 |
| 17 | Adaptive Biotechnologies 1, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177409 | CEO total compensation as printed in Adaptive Biotechnologies 1's own proxy. As printed: 9,081,690. Filing ↗machine: span 818708–818717 |
| 18 | Standard BioTools, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001140361-26-017100 | CEO total compensation as printed in Standard BioTools's own proxy. As printed: 8,823,502. Filing ↗machine: r2 · c22 · span 553256–553266 |
| 19 | Veracyte, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001384101-26-000021 | CEO total compensation as printed in Veracyte's own proxy. As printed: 7,421,877. Filing ↗machine: r4 · c27 · span 855413–855422 |
| 20 | CareDx, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001217234-26-000028 | CEO total compensation as printed in CareDx's own proxy. As printed: 7,179,699. Filing ↗machine: t113 · r3 · c9 · span 1893652–1893661 |
| 21 | Castle Biosciences, Section 10b CEO total | DEF 14A | 2026-04-08 | 0001628280-26-024166 | CEO total compensation as printed in Castle Biosciences's own proxy. As printed: 6,786,771. Filing ↗machine: r3 · c24 · span 933087–933096 |
| 22 | Mesa Laboratories 1, Section 10b CEO total | DEF 14A | 2026-07-22 | 0000724004-26-000071 | CEO total compensation as printed in Mesa Laboratories 1's own proxy. As printed: 6,643,208. Filing ↗machine: r3 · c24 · span 580946–580955 |
| 23 | Fulgent Genetics 1, Section 10b CEO total | DEF 14A | 2026-03-31 | 0001674930-26-000020 | CEO total compensation as printed in Fulgent Genetics 1's own proxy. As printed: 6,207,000. Filing ↗machine: r3 · c22 · span 533279–533288 |
| 24 | Quanterix, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001104659-26-048166 | CEO total compensation as printed in Quanterix's own proxy. As printed: 5,250,745. Filing ↗machine: t18 · r1 · c47 · span 503076–503085 |
| 25 | CytomX Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001140361-26-018237 | CEO total compensation as printed in CytomX Therapeutics's own proxy. As printed: 4,738,495. Filing ↗machine: r2 · c24 · span 739353–739362 |
| 26 | Pacific Biosciences of California, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001299130-26-000064 | CEO total compensation as printed in Pacific Biosciences of California's own proxy. As printed: 4,309,846. Filing ↗machine: r2 · c48 · span 876974–876983 |
| 27 | OraSure Technologies, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001116463-26-000032 | CEO total compensation as printed in OraSure Technologies's own proxy. As printed: 4,292,228. Filing ↗machine: t152 · r2 · c21 · span 850376–850385 |
| 28 | Personalis (subject), Section 10b CEO total | DEF 14A | 2026-04-02 | 0001193125-26-140038 | CEO total compensation as printed in Personalis's own proxy. As printed: 3,505,978. Filing ↗machine: r2 · c25 · span 489936–489945 |
| 29 | Codexis, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186994 | CEO total compensation as printed in Codexis's own proxy. As printed: 2,323,279. Filing ↗machine: r2 · c27 · span 319928–319937 |
| 30 | Alector, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186928 | CEO total compensation as printed in Alector's own proxy. As printed: 1,995,018. Filing ↗machine: span 1038665–1038674 |
| 31 | Sutro Biopharma 1, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001193125-26-170354 | CEO total compensation as printed in Sutro Biopharma 1's own proxy. As printed: 1,671,311. Filing ↗machine: t15 · r6 · c29 · span 726958–726967 |
| 32 | Section 10a, Castle Biosciences reciprocity | DEF 14A | — | 0001628280-26-024166 | Castle Biosciences's most recent proxy was read; its disclosed peer group does not include Personalis. Filing ↗ |
| 33 | Section 10a, Veracyte reciprocity | DEF 14A | — | 0001384101-26-000021 | Veracyte's most recent proxy was read; its disclosed peer group does not include Personalis. Filing ↗ |
| 34 | Section 10a, Alector reciprocity | DEF 14A | — | 0001193125-26-186928 | Alector's most recent proxy was read; its disclosed peer group does not include Personalis. Filing ↗ |
| 35 | Section 10a, Mesa Laboratories 1 reciprocity | DEF 14A | — | 0000724004-26-000071 | Mesa Laboratories 1's most recent proxy was read; its disclosed peer group does not include Personalis. Filing ↗ |
| 36 | Section 10a, OraSure Technologies reciprocity | DEF 14A | — | 0001116463-26-000032 | OraSure Technologies names Personalis in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 37 | Section 10a, Standard BioTools reciprocity | DEF 14A | — | 0001140361-26-017100 | Standard BioTools's most recent proxy was read; its disclosed peer group does not include Personalis. Filing ↗ |
| 38 | Section 10a, CareDx reciprocity | DEF 14A | — | 0001217234-26-000028 | CareDx's most recent proxy was read; its disclosed peer group does not include Personalis. Filing ↗ |
| 39 | Section 10a, Codexis reciprocity | DEF 14A | — | 0001193125-25-093503 | Codexis names Personalis in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 40 | Section 10a, Pacific Biosciences of California reciprocity | DEF 14A | — | 0001299130-26-000064 | Pacific Biosciences of California's most recent proxy was read; its disclosed peer group does not include Personalis. Filing ↗ |
| 41 | Section 10a, Quanterix reciprocity | DEF 14A | — | 0001104659-26-048166 | Quanterix's most recent proxy was read; its disclosed peer group does not include Personalis. Filing ↗ |
| 42 | Section 10a, GeneDx reciprocity | DEF 14A | — | 0001818331-26-000030 | GeneDx's most recent proxy was read; its disclosed peer group does not include Personalis. Filing ↗ |
| 43 | Section 10a, Sutro Biopharma 1 reciprocity | DEF 14A | — | 0001193125-26-170354 | Sutro Biopharma 1's most recent proxy was read; its disclosed peer group does not include Personalis. Filing ↗ |
| 44 | Section 10a, Adaptive Biotechnologies 1 reciprocity | DEF 14A | — | 0001193125-26-177409 | Adaptive Biotechnologies 1's most recent proxy was read; its disclosed peer group does not include Personalis. Filing ↗ |
| 45 | Section 10a, Fulgent Genetics 1 reciprocity | DEF 14A | — | 0001674930-26-000020 | Fulgent Genetics 1's most recent proxy was read; its disclosed peer group does not include Personalis. Filing ↗ |